Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Olav who wrote (67009)	1/26/2000 9:24:00 AM
From: Mr_Mojo_Risin	Read Replies (1) \| Respond to of 108040

PLRX up 2 1/2 on good sequentials.....KOREA looks like a (hopeful) bottom.....CLIC holding in 37 range mojo!

To: Olav who wrote (67009)	1/26/2000 9:24:00 AM
From: hoffy	Respond to of 108040

AVAN big news. Wednesday January 26, 8:29 am Eastern Time Company Press Release SOURCE: AVANT Immunotherapeutics, Inc. Avant Immunotherapeutics Announces a Cooperative Research and Development Agreement With Walter Reed Army Institute For Candidate HIV/AIDS Vaccine NEEDHAM, Mass., Jan. 26 /PRNewswire/ -- AVANT Immunotherapetics, Inc. (Nasdaq: AVAN - news) announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) for the use of Therapore(TM)-P24 in the development of a vaccine candidate against the Human Immunodeficiency Virus (HIV). Under the CRADA, AVANT will provide its proprietary Therapore(TM) technology, which the company believes, offers significant advantages over other immunotherapeutic methods. Therapore will be used to generate specific immune responses against the HIV genomic sequence. Experts believe that an immune response created by a vaccine against the gene carried inside HIV has the potential to prevent infection by the virus and subsequently to protect individuals from developing Acquired Immunodeficiency Syndrome (AIDS). AVANT and WRAIR will each produce a component of the vaccine to be used in a clinical trial that will be run at WRAIR. ''We are delighted to enter into this cooperative agreement with WRAIR and to begin a clinical trial to demonstrate the proof-of-concept for our Therapore(TM) program,'' said Una Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapetics, Inc. ''We believe that this technology will be useful against a wide variety of diseases, such as cancer and certain chronic viral infections.''